Iowa Department of Human Services

Terry E. Branstad
Governor

Kim Reynolds
Lt. Governor

Charles M. Palmer
Director

Iowa Medicaid Drug Utilization Review (DUR) Commission Meeting

October 7, 2015

Location: Learning Resource Center
Fairmeadows Room
3550 Mills Civic Parkway
West Des Moines, Iowa 50265

Time: 9:30 a.m. – 1:30 p.m.

Tentative Agenda

1. Welcome & Introductions
    a) Commission Members and Staff
    b) Approval of the Minutes
2. Commission Business
    a) DHS Recommendation Letter – August 2015
    b) P&T Recommendation Letter – August 2015
3. IME Updates
4. Prevalence Report Summary
5. Case Studies
6. Public Comment (See Conflict of Interest Disclosure Form)
7. Focus Studies/Provider Education Initiatives
    a) Short-Acting Opioid Overutilization – Four or More Doses Per Day – Follow Up
    b) Duplicate Inhaled Corticosteroids – Initial Review
    c) Duplicate Long-Acting Beta-2 Agonists – Initial Review
8. Public Comment (See Conflict of Interest Disclosure Form)
9. Prior Authorization
    a) Annual Review of Prior Authorization Criteria
    b) Growth Hormone – Initial Review
    c) PCSK9 Inhibitors – Initial Review
    d) Cholic Acid (Cholbam®) – Initial Review
    e) Binge Eating Disorder Agents – Initial Review

f) Topical Antifungals for Onychomycosis – Second Review

g) Alpha-1 Proteinase Inhibitors – Second Review

h) Lumacaftor/Ivacaftor (Orkambi™) – Second Review

i) Biologicals for Ankylosing Spondylitis – Second Review

j) Biologicals for Inflammatory Bowel Disease – Second Review

k) Biologicals for Plaque Psoriasis – Second Review

l) Select Oncology Agents – Second Review

10. Miscellaneous

a) DUR Digest Vol. 28, No. 1 – Second Review

b) MedWatch

11. Executive Closed Session

a) Approval of Minutes

b) Member Profiles

12. Adjournment

Individuals attending meetings of the DUR Commission shall have an opportunity to address the Commission. This opportunity will be granted twice during the open portion of the meeting. In order to accommodate all interested parties, all speakers are requested to limit their comments to **5 minutes or less**. If you represent a drug manufacturer as an employee, as a contractor, as a member of the manufacturer's Speaker Bureau, or by any other means, we expect you to cover your individual product or entire product line in that five-minute time frame. Speakers who represent multiple manufacturers will share their 5 minutes with the other manufacturer representative(s) whose product they are speaking on.

www.iadur.org

For more information contact the DUR Project Coordinator, Pamela Smith, R.Ph., at info@iadur.org or (515) 974-3131

*****Next Meeting December 2, 2015*****
Learning Resource Center
West Des Moines, IA